HECT domain E3 ubiquitin protein ligase 4 (HECTD4) is an enzyme that plays a pivotal role in the ubiquitin-proteasome system, a cellular mechanism critical for the regulation of protein turnover and quality control within the cell. E3 ubiquitin ligases such as HECTD4 are instrumental in targeting specific proteins for ubiquitination, a process where multiple ubiquitin molecules are attached to a substrate protein, marking it for degradation by the proteasome or altering its cellular location, activity, or interactions.The structure of HECTD4 includes the highly conserved HECT domain, which is involved in the direct transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to the substrate protein. This transfer is a two-step reaction where the HECT domain first forms a thioester bond with ubiquitin and then facilitates its transfer to the lysine residues of the substrate protein. The HECT domain's unique ability to form this intermediate complex with ubiquitin distinguishes HECT-type ligases from other E3 ligases.
HECTD4's substrates and biological functions are not fully characterized, but it is known that the activity of HECT-type ligases is intricately regulated and often sensitive to cellular cues, enabling dynamic responses to physiological stimuli. Given the general role of E3 ubiquitin ligases in cellular processes such as signal transduction, cell cycle control, and immune responses, HECTD4 is likely to be involved in similar pathways, contributing to cellular homeostasis and the response to stress or damage.Dysfunction in E3 ligases like HECTD4 can lead to the accumulation of misfolded or damaged proteins, potentially contributing to the development of various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can increase cellular ubiquitin levels, potentially affecting E3 ligase activity. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
This compound is known to inhibit E1 enzyme and thus could indirectly reduce E3 ligase activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
Inhibits the NEDD8-activating enzyme, which is necessary for the activation of certain E3 ligases. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Irreversibly binds to and inhibits the proteasome, potentially affecting ubiquitin-proteasome system dynamics. | ||||||
ETC-159 | 1638250-96-0 | sc-507415 | 5 mg | $90.00 | ||
An inhibitor of endoplasmic reticulum-associated degradation (ERAD), part of the ubiquitin-proteasome pathway. | ||||||
NSC697923 | 343351-67-7 | sc-391107 sc-391107A | 1 mg 5 mg | $15.00 $51.00 | 3 | |
A small molecule that inhibits the UBE2N ubiquitin-conjugating enzyme, affecting E3 ligase activity. | ||||||